Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
| ▸ | ACACB | O00763 | 15/20 | 0.42 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.38 |
| ▸ | AKT1 | P31749 | 2/20 | 0.34 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.34 |
| ▸ | AKT2 | P31751 | 1/20 | 0.34 |
| ▸ | AKT3 | Q9Y243 | 1/20 | 0.34 |
| ▸ | JAK3 | P52333 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL83976 | 0.84 | ACACB (0.40) | SIGMAR1ACACBFFAR2 | |
| SCHEMBL10074499 | 0.81 | ACACB (0.44) | ACACBAKT2JAK3 | |
| SCHEMBL10074500 | 0.80 | ACACB (0.43) | SIGMAR1ACACBAKT2JAK3 | |
| SCHEMBL10074502 | 0.80 | ACACB (0.43) | SIGMAR1ACACBAKT2JAK3 | |
| SCHEMBL10073993 | 0.79 | ACACB (0.44) | SIGMAR1ACACBFFAR2AKT1RPS6KB1 | |
| SCHEMBL82711 | 0.77 | SIGMAR1 (0.37) | SIGMAR1ACACBFFAR2JAK3 | |
| SCHEMBL10074501 | 0.72 | ACACB (0.43) | ACACB | |
| SCHEMBL1628329 | 0.70 | ACACB (0.46) | ACACBAKT2JAK3 | |
| SCHEMBL10074122 | 0.69 | ACACB (0.45) | ACACBAKT2JAK3 | |
| SCHEMBL1629504 | 0.69 | ACACB (0.45) | ACACBAKT2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120088914-A1 | PRODUCTION METHOD OF PYRIMIDINE COMPOUNDS | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088914-A1 | PRODUCTION METHOD OF PYRIMIDINE COMPOUNDS | DPYD, DHFR, DHODH | SIGMAR1 2950/4885ACACB 426/4885FFAR2 1295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.